You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
郭思治: 昨天大市在动力配合下突破 技术上高一线
阿思达克 07-03 09:40
香港股票分析师协会副主席郭思治称,大市踏进七月份首个交易日已见突破。恒指昨天先高开136点至24563点,其後在资金力捧下逐步推上,最後更以全日最高位收市。恒指报收25124点,较上日急升697点,而全日总成交金额为1759亿元。单从走势上看,由於恒指已渐升离50天线,故暂不用担心会有试底之险。另外,经昨天之急升,恒指已一举重越10天线(24619点)、20天线(24572点)及100天线(24663点),即技术上已初呈欲试顶之趋势。而所指的顶,暂该为6月10日之高位25303点。只要大市能成功升越此关,即表示自3月19日低位21139点开始之反弹,技术上已渐呈浪高於浪之形态。

昨天是七月份首个交易日。恒指是由早市之低位24563点升至收市之25124点,即走势上是典型之由头升到尾,且亦有达1759亿元之成交金额支持。大市此番突破是在庞大动力支持下进行,故技术上该可稍看高一线。由於成交金额是走在指数前头,故此在七月上旬时分,该有更高之指数在後头。

永泰生物(06978.HK)的EAR为首个开始实体瘤临床试验的细胞免疫治疗产品,以肝癌为适应症,2018年中国肝癌的新增病例超过40万,占全球肝癌新增病例的44.9%,相关病例由2014年的360,000宗上升到2018年的400,200宗,估计至2030年将达至506,000宗,而有关中国的细胞免疫治疗产品市场规模预计於2021年至2023年,将由13亿元人民币升至102亿元人民币,以人均费用一至两万元人民币,而使用次数约八至20次计,EAL的市场空间已高达720亿元人民币至3500亿元人民币,即未来之发展空间极大,投资者在照顾时不妨多加关注。(笔者为证监会持牌人士)~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account